

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: SOL Global Investments Corp. (the "Issuer").

Trading Symbol: SOL

Number of Outstanding Listed Securities: 54,629,256

Date: August 7, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website. This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

On July 8, 2019, the Issuer announced that it has completed a \$50,000,000 private placement financing (the "Transaction") by way of the issue and sale of a senior secured non-convertible debenture (the "Debenture") to an arm's length institutional investor (the "Lender"). The Debenture bears an interest rate of 6.0% per annum and will mature two (2) years from the date of closing, unless such maturity date is otherwise shortened due to the occurrence of certain independent milestones as set out within the terms and conditions of the Debenture. The Debenture may be repaid by the Issuer in cash or in-kind with securities held within the Issuer's investment portfolio. The Debenture is not dilutive to the Issuer's shareholders.

On July 8, 2019, the Issuer announced that Jonathan Gilbert resigned as President of Impact Biosciences Corp ("Impact"), an 100% owned investee company of the Issuer. It was also announced that the capital raise that Impact was contemplating was discontinued. As a result, Impact will remain 100% owned by the Issuer.

On July 12, 2019, the Issuer announced that it has purchased 37,662,500 common shares of Heavenly Rx Ltd. ("Heavenly Rx") at a price of \$0.40. Further, on July 29, 2019 the Issuer announced that it has purchased an additional 16,766,250 common shares at a price of \$0.40 for an aggregate subscription amount of CAD\$23,909,000. The Issuer now owns 44.53% of Heavenly Rx's issued and outstanding shares.

On July 17, 2019 the Issuer purchased US\$6.5 million (CAD\$8,494,000) in CannCure Investments Inc. ("CannCure") financing. Further, on July 25, 2019 the Issuer announced a US\$2 million (CAD\$2,628,960.00) capital infusion in CannCure. As a result of this, the Issuer's ownership has increased to 97.9%. Upon CannCure's completion of its previously announced acquisitions in California and Michigan, as well as completing the payment of the USD\$80,000,000 earn out to the former owners of CannCure, as previously announced on April 1, 2019, SOL Global expects to own approximately 20.6% of the resulting business.

2. Describe the acquisition of new customers or loss of customers.

None noted.

3. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None noted.

4. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None noted.

5. Report on any labour disputes and resolutions of those disputes if applicable.

None noted.

6. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None noted.

7. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

On July 8, 2019, the Issuer announced that it has completed a \$50,000,000 private placement financing (the "Transaction") by way of the issue and sale of a senior secured non-convertible debenture (the "Debenture") to an arm's length institutional investor (the "Lender"). The Debenture bears an interest rate of 6.0% per annum and will mature two (2) years from the date of closing, unless such maturity date is otherwise shortened due to the occurrence of certain independent milestones as set out within the terms and conditions of the Debenture. The Debenture may be repaid by the Issuer in cash or in-kind with securities held within the Issuer's investment portfolio. The Debenture is not dilutive to the Issuer's shareholders.

8. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
DSUs	1,512,000	Issued to Employees and Consultants	No cash consideration received.

9. Provide details of any loans to or by Related Persons.

None noted.

10. Provide details of any changes in directors, officers or committee members.

On July 8, 2019, the Issuer announced that Jonathan Gilbert resigned as President of Impact Biosciences Corp ("Impact"), an 100% owned investee company of the Issuer.

On July 31, 2019, the Issuer announced Judge Jeanine Pirro to the Board of Directors of its investee company, Heavenly Rx Ltd.

11. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None noted.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: August 7, 2019.

Peter Liabotis
 Name of Director or Senior Officer
/s/ "Peter Liabotis"
 Signature
CFO
 Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer SOL Global Investments Corp.		July 2019	YY/MM/D 19/08/07
Issuer Address 5600-100 King St. West			
City/Province/Postal Code Toronto, ON, M5X 1C9		Issuer Fax No. ()	Issuer Telephone No. (212) 729-9208
Contact Name Peter Liabotis		Contact Position CFO	Contact Telephone No. (212) 729-9208
Contact Email Address info@solglobal.com		Web Site Address https://solglobal.com/	